Filing Flows › Organogenesis Holdings (ORGO) › Q3 2026 › vs Q3 2025
Organogenesis Holdings (ORGO) Q3 2026 vs Q3 2025 (year over year)
Organogenesis Holdings's revenue fell $105M (-70%) from $151M in Q3 2025 to $45.5M in Q3 2026.
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $45.5M | $151M | −$105M | -70% |
| Net loss | $29.6M | −$21.6M | $51.2M | — |
| Costs & expenses | $75.1M | $152M | −$76.6M | -51% |
| Operating costs | $74.9M | $130M | −$55.2M | -42% |
| Income tax | $8K | −$407K | $415K | — |
| Research & development | $8.0M | $13.2M | −$5.3M | -40% |
| SG&A | $45.1M | $79.7M | −$34.7M | -43% |
| Other operating costs | $21.9M | $37.2M | −$15.3M | -41% |
| Operating cash sources | $29.6M | −$21.6M | $51.2M | — |
| Depreciation & amortization | $3.9M | $4.9M | −$944K | -19% |
| Share-based compensation | $2.8M | $3.1M | −$259K | -8% |
| Working capital & other | $4.3M | −$26.4M | $30.7M | — |
| Cash used in operations | $18.6M | −$3.1M | $21.7M | — |
| Net loss absorbed | $29.6M | −$21.6M | $51.2M | — |
Questions
How much did Organogenesis Holdings's revenue grow year over year in Q3 2026?
Organogenesis Holdings's revenue fell $105M (-70%) from $151M in Q3 2025 to $45.5M in Q3 2026.